Mohammed Khan, MD
Interventional Pain Medicine · Coppell, TXNPI 1891982278
Payments from drug & device makers
Across 90 payments — averaging $51.86 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Genesys Orthopedics Systems, L.L.C.$1K
- Vertiflex, Inc.$891
- Abbott$615
- Relievant Medsystems, Inc.$520
- Boston Scientific$429
- Medtronic$392
- plus $418 from 8 others
What the payments were for
- Travel & lodging$2,98064%
- Food & beverage$1,67236%
- Gifts$150%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Genesys Orthopedics Systems, L.L.C. | 7 | $1,403 |
| Vertiflex, Inc. | 5 | $891 |
| Abbott | 4 | $615 |
| Relievant Medsystems, Inc. | 7 | $520 |
| Boston Scientific | 37 | $429 |
| Medtronic(2 entities) | 16 | $392 |
| Globus Medical | 6 | $281 |
| Nevro Corp. | 2 | $37 |
| Stryker | 1 | $25 |
| Bioventus LLC | 1 | $21 |
| Fidia Pharma USA Inc. | 1 | $15 |
| AstraZeneca | 1 | $15 |
| GSK | 1 | $12 |
| Sage Therapeutics, LLC | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- SACROILIAC JOINT FUSION SYSTEM$1,208
- Superion ISS$812
- PROCLAIM$587
- Intracept$365
- Senza$116
How this compares
$4,667 in reported general payments places this provider in the 40th percentile of 287 interventional pain medicine providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 281 | $8,084 |
| Hydromorphone Hcl | 11 | $1,453 |
| Acetaminophen-CodeineAcetaminophen With Codeine | 20 | $697 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 14 | $666 |
| Morphine Sulfate | 18 | $663 |
| Oxycodone Hcl | 20 | $575 |
| Gabapentin | 27 | $240 |
| Celecoxib | 14 | $239 |
| Tizanidine Hcl | 20 | $192 |
| Cyclobenzaprine Hcl | 15 | $160 |
| Tramadol Hcl | 17 | $63 |
Paid to pharmacies, not to this prescriber.
Other interventional pain medicine in Coppell
- Gabor RaczLubbock$3M
- Pankaj MehtaKilleen$2.2M
- Genaro GutierrezAustin$1.3M
- Chad StephensSouthlake$1.1M
- Ioannis SkaribasHouston$979K
- Duane GriffithTyler$730K
- Brannon FrankAustin$698K
- Robert WillsRound Rock$692K
- Ankur KhoslaShenandoah$511K
- Brian RichDecatur$245K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.